Entasis Therapeutics Holdings Inc. announced that the company presented data highlights from its pivotal Phase 3 ATTACK trial at the American Thoracic Society (ATS) annual conference, held this week from May 16-18, 2022, in San Francisco, California. The poster presentation?P628 Sulbactam-Durlobactam (SUL-DUR) Treatment Is Associated with Lower Mortality from Index Acinetobacter Infections in the Attack Phase 3 Registrational Trial?presented key data from the landmark ATTACK trial. Sulbactam-durlobactam is an investigational drug in development for the treatment of infections caused by Acinetobacter baumannii including carbapenem-resistant and multi-drug resistant strains.

Key findings in this presentation include: There was a notable divergence in all-cause mortality between days 6-14 with higher rates of mortality in the colistin treatment arm. All-cause mortality rates were similar in the SUL-DUR and colistin arms during days 0-5 and 15-28 after the start of therapy Twice as many deaths occurred in the colistin arm than in the SUL-DUR arm through Day 28 Investigator-assessed deaths related to the index carbapenem-resistant Acinetobacter baumannii-calcoaceticus infection occurred more frequently during days 6-14 in the colistin arm Patients in the colistin arm who died during days 6-14 (60 ± 16 years) were younger than patients who died during days 0-5/15-28 (78 ± 12 years) These observations suggest that deaths early in treatment were more attributed to failure of treatment of Acinetobacter while deaths later in treatment were due to underlying co-morbidities. The ATTACK trial was conducted to evaluate the efficacy and safety of SUL-DUR versus colistin, both in combination with imipenem/cilastatin, for patients with Acinetobacter baumannii-calcoaceticus (ABC) infections, including carbapenem-resistant and multidrug-resistant strains.

The trial consisted of two parts: Part A was a randomized, blinded noninferiority study (SUL-DUR versus colistin; non-inferiority margin 20%) in ABC hospital-acquired pneumonia, ventilator-associated bacterial pneumonia, ventilated pneumonia, or bacteremia; Part B was an open label study (SUL-DUR only) that enrolled patients with ABC infections who did not tolerate colistin/polymyxin B or whose pathogens were resistant to colistin/polymyxin B.